S&P 500   3,909.32 (+2.58%)
DOW   31,602.82 (+2.17%)
QQQ   323.61 (+3.01%)
AAPL   127.50 (+5.15%)
MSFT   236.98 (+1.98%)
FB   266.15 (+3.31%)
GOOGL   2,069.97 (+2.38%)
TSLA   713.92 (+5.69%)
AMZN   3,141.47 (+1.57%)
NVDA   550.13 (+0.28%)
BABA   241.58 (+1.61%)
CGC   34.72 (+6.02%)
GE   13.21 (+5.34%)
MU   94.68 (+3.44%)
NIO   49.72 (+8.61%)
AMD   86.36 (+2.19%)
T   28.17 (+1.00%)
F   12.04 (+2.91%)
ACB   11.12 (+5.70%)
DIS   195.23 (+3.27%)
BA   224.78 (+6.02%)
NFLX   549.87 (+2.05%)
BAC   36.00 (+3.72%)
S&P 500   3,909.32 (+2.58%)
DOW   31,602.82 (+2.17%)
QQQ   323.61 (+3.01%)
AAPL   127.50 (+5.15%)
MSFT   236.98 (+1.98%)
FB   266.15 (+3.31%)
GOOGL   2,069.97 (+2.38%)
TSLA   713.92 (+5.69%)
AMZN   3,141.47 (+1.57%)
NVDA   550.13 (+0.28%)
BABA   241.58 (+1.61%)
CGC   34.72 (+6.02%)
GE   13.21 (+5.34%)
MU   94.68 (+3.44%)
NIO   49.72 (+8.61%)
AMD   86.36 (+2.19%)
T   28.17 (+1.00%)
F   12.04 (+2.91%)
ACB   11.12 (+5.70%)
DIS   195.23 (+3.27%)
BA   224.78 (+6.02%)
NFLX   549.87 (+2.05%)
BAC   36.00 (+3.72%)
S&P 500   3,909.32 (+2.58%)
DOW   31,602.82 (+2.17%)
QQQ   323.61 (+3.01%)
AAPL   127.50 (+5.15%)
MSFT   236.98 (+1.98%)
FB   266.15 (+3.31%)
GOOGL   2,069.97 (+2.38%)
TSLA   713.92 (+5.69%)
AMZN   3,141.47 (+1.57%)
NVDA   550.13 (+0.28%)
BABA   241.58 (+1.61%)
CGC   34.72 (+6.02%)
GE   13.21 (+5.34%)
MU   94.68 (+3.44%)
NIO   49.72 (+8.61%)
AMD   86.36 (+2.19%)
T   28.17 (+1.00%)
F   12.04 (+2.91%)
ACB   11.12 (+5.70%)
DIS   195.23 (+3.27%)
BA   224.78 (+6.02%)
NFLX   549.87 (+2.05%)
BAC   36.00 (+3.72%)
S&P 500   3,909.32 (+2.58%)
DOW   31,602.82 (+2.17%)
QQQ   323.61 (+3.01%)
AAPL   127.50 (+5.15%)
MSFT   236.98 (+1.98%)
FB   266.15 (+3.31%)
GOOGL   2,069.97 (+2.38%)
TSLA   713.92 (+5.69%)
AMZN   3,141.47 (+1.57%)
NVDA   550.13 (+0.28%)
BABA   241.58 (+1.61%)
CGC   34.72 (+6.02%)
GE   13.21 (+5.34%)
MU   94.68 (+3.44%)
NIO   49.72 (+8.61%)
AMD   86.36 (+2.19%)
T   28.17 (+1.00%)
F   12.04 (+2.91%)
ACB   11.12 (+5.70%)
DIS   195.23 (+3.27%)
BA   224.78 (+6.02%)
NFLX   549.87 (+2.05%)
BAC   36.00 (+3.72%)
Log in
NYSE:HAE

Haemonetics Competitors

$128.35
+1.85 (+1.46 %)
(As of 03/1/2021 03:07 PM ET)
Add
Compare
Today's Range
$127.43
Now: $128.35
$130.73
50-Day Range
$114.05
MA: $127.77
$139.48
52-Week Range
$63.41
Now: $128.35
$142.11
Volume4,444 shs
Average Volume374,645 shs
Market Capitalization$6.52 billion
P/E Ratio62.01
Dividend YieldN/A
Beta0.56

Competitors

Haemonetics (NYSE:HAE) Vs. ALGN, WST, COO, XRAY, QDEL, and STAA

Should you be buying HAE stock or one of its competitors? Companies in the sub-industry of "health care supplies" are considered alternatives and competitors to Haemonetics, including Align Technology (ALGN), West Pharmaceutical Services (WST), The Cooper Companies (COO), DENTSPLY SIRONA (XRAY), Quidel (QDEL), and STAAR Surgical (STAA).

Align Technology (NASDAQ:ALGN) and Haemonetics (NYSE:HAE) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings and institutional ownership.

Profitability

This table compares Align Technology and Haemonetics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Align Technology76.00%68.99%46.64%
Haemonetics11.76%22.85%10.40%

Analyst Recommendations

This is a summary of recent ratings for Align Technology and Haemonetics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Align Technology14902.57
Haemonetics00503.00

Align Technology presently has a consensus price target of $475.4615, indicating a potential downside of 16.03%. Haemonetics has a consensus price target of $144.80, indicating a potential upside of 13.19%. Given Haemonetics' stronger consensus rating and higher possible upside, analysts plainly believe Haemonetics is more favorable than Align Technology.

Volatility & Risk

Align Technology has a beta of 1.68, indicating that its share price is 68% more volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500.

Insider and Institutional Ownership

85.8% of Align Technology shares are held by institutional investors. Comparatively, 96.2% of Haemonetics shares are held by institutional investors. 1.2% of Align Technology shares are held by company insiders. Comparatively, 1.6% of Haemonetics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Align Technology and Haemonetics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Align Technology$2.41 billion18.55$442.78 million$4.96114.16
Haemonetics$988.48 million6.58$76.53 million$3.3138.65

Align Technology has higher revenue and earnings than Haemonetics. Haemonetics is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Summary

Align Technology beats Haemonetics on 9 of the 14 factors compared between the two stocks.

West Pharmaceutical Services (NYSE:WST) and Haemonetics (NYSE:HAE) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, valuation, risk, analyst recommendations and institutional ownership.

Profitability

This table compares West Pharmaceutical Services and Haemonetics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
West Pharmaceutical Services14.69%19.01%12.78%
Haemonetics11.76%22.85%10.40%

Earnings & Valuation

This table compares West Pharmaceutical Services and Haemonetics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
West Pharmaceutical Services$1.84 billion11.40$241.70 million$3.2487.35
Haemonetics$988.48 million6.58$76.53 million$3.3138.65

West Pharmaceutical Services has higher revenue and earnings than Haemonetics. Haemonetics is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for West Pharmaceutical Services and Haemonetics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
West Pharmaceutical Services01202.67
Haemonetics00503.00

West Pharmaceutical Services presently has a consensus price target of $310.00, indicating a potential upside of 9.54%. Haemonetics has a consensus price target of $144.80, indicating a potential upside of 13.19%. Given Haemonetics' stronger consensus rating and higher possible upside, analysts clearly believe Haemonetics is more favorable than West Pharmaceutical Services.

Risk & Volatility

West Pharmaceutical Services has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500.

Insider and Institutional Ownership

92.6% of West Pharmaceutical Services shares are held by institutional investors. Comparatively, 96.2% of Haemonetics shares are held by institutional investors. 1.6% of West Pharmaceutical Services shares are held by insiders. Comparatively, 1.6% of Haemonetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

The Cooper Companies (NYSE:COO) and Haemonetics (NYSE:HAE) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Institutional and Insider Ownership

95.8% of The Cooper Companies shares are held by institutional investors. Comparatively, 96.2% of Haemonetics shares are held by institutional investors. 1.4% of The Cooper Companies shares are held by company insiders. Comparatively, 1.6% of Haemonetics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares The Cooper Companies and Haemonetics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The Cooper Companies$2.43 billion7.99$238.40 million$9.6440.98
Haemonetics$988.48 million6.58$76.53 million$3.3138.65

The Cooper Companies has higher revenue and earnings than Haemonetics. Haemonetics is trading at a lower price-to-earnings ratio than The Cooper Companies, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for The Cooper Companies and Haemonetics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
The Cooper Companies04702.64
Haemonetics00503.00

The Cooper Companies currently has a consensus target price of $360.0769, suggesting a potential downside of 8.84%. Haemonetics has a consensus target price of $144.80, suggesting a potential upside of 13.19%. Given Haemonetics' stronger consensus rating and higher probable upside, analysts clearly believe Haemonetics is more favorable than The Cooper Companies.

Profitability

This table compares The Cooper Companies and Haemonetics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
The Cooper Companies9.81%12.79%7.20%
Haemonetics11.76%22.85%10.40%

Risk & Volatility

The Cooper Companies has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500.

DENTSPLY SIRONA (NASDAQ:XRAY) and Haemonetics (NYSE:HAE) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent recommendations for DENTSPLY SIRONA and Haemonetics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DENTSPLY SIRONA17702.40
Haemonetics00503.00

DENTSPLY SIRONA currently has a consensus target price of $51.7857, suggesting a potential downside of 13.73%. Haemonetics has a consensus target price of $144.80, suggesting a potential upside of 13.19%. Given Haemonetics' stronger consensus rating and higher probable upside, analysts clearly believe Haemonetics is more favorable than DENTSPLY SIRONA.

Profitability

This table compares DENTSPLY SIRONA and Haemonetics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DENTSPLY SIRONA-1.40%7.13%4.13%
Haemonetics11.76%22.85%10.40%

Insider & Institutional Ownership

96.0% of DENTSPLY SIRONA shares are owned by institutional investors. Comparatively, 96.2% of Haemonetics shares are owned by institutional investors. 0.5% of DENTSPLY SIRONA shares are owned by company insiders. Comparatively, 1.6% of Haemonetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

DENTSPLY SIRONA has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500.

Earnings & Valuation

This table compares DENTSPLY SIRONA and Haemonetics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DENTSPLY SIRONA$4.03 billion3.26$262.90 million$2.4524.50
Haemonetics$988.48 million6.58$76.53 million$3.3138.65

DENTSPLY SIRONA has higher revenue and earnings than Haemonetics. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Summary

Haemonetics beats DENTSPLY SIRONA on 10 of the 14 factors compared between the two stocks.

Haemonetics (NYSE:HAE) and Quidel (NASDAQ:QDEL) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings for Haemonetics and Quidel, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Haemonetics00503.00
Quidel11302.40

Haemonetics currently has a consensus price target of $144.80, suggesting a potential upside of 13.19%. Quidel has a consensus price target of $245.60, suggesting a potential upside of 45.55%. Given Quidel's higher probable upside, analysts plainly believe Quidel is more favorable than Haemonetics.

Profitability

This table compares Haemonetics and Quidel's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Haemonetics11.76%22.85%10.40%
Quidel36.91%63.31%40.55%

Institutional & Insider Ownership

96.2% of Haemonetics shares are owned by institutional investors. Comparatively, 84.0% of Quidel shares are owned by institutional investors. 1.6% of Haemonetics shares are owned by insiders. Comparatively, 14.1% of Quidel shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Haemonetics has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, Quidel has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500.

Valuation and Earnings

This table compares Haemonetics and Quidel's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Haemonetics$988.48 million6.58$76.53 million$3.3138.65
Quidel$534.89 million13.35$72.92 million$2.7361.81

Haemonetics has higher revenue and earnings than Quidel. Haemonetics is trading at a lower price-to-earnings ratio than Quidel, indicating that it is currently the more affordable of the two stocks.

Summary

Haemonetics beats Quidel on 8 of the 14 factors compared between the two stocks.

Haemonetics (NYSE:HAE) and STAAR Surgical (NASDAQ:STAA) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Profitability

This table compares Haemonetics and STAAR Surgical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Haemonetics11.76%22.85%10.40%
STAAR Surgical5.73%8.99%7.12%

Analyst Ratings

This is a breakdown of current ratings for Haemonetics and STAAR Surgical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Haemonetics00503.00
STAAR Surgical03302.50

Haemonetics currently has a consensus price target of $144.80, suggesting a potential upside of 13.19%. STAAR Surgical has a consensus price target of $68.50, suggesting a potential downside of 34.82%. Given Haemonetics' stronger consensus rating and higher probable upside, analysts plainly believe Haemonetics is more favorable than STAAR Surgical.

Volatility and Risk

Haemonetics has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, STAAR Surgical has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500.

Institutional & Insider Ownership

96.2% of Haemonetics shares are owned by institutional investors. Comparatively, 85.4% of STAAR Surgical shares are owned by institutional investors. 1.6% of Haemonetics shares are owned by insiders. Comparatively, 3.9% of STAAR Surgical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Haemonetics and STAAR Surgical's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Haemonetics$988.48 million6.58$76.53 million$3.3138.65
STAAR Surgical$150.18 million32.59$14.05 million$0.46228.48

Haemonetics has higher revenue and earnings than STAAR Surgical. Haemonetics is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.

Summary

Haemonetics beats STAAR Surgical on 10 of the 14 factors compared between the two stocks.


Haemonetics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Align Technology logo
ALGN
Align Technology
2.0$566.23+0.2%$44.72 billion$2.41 billion25.76
West Pharmaceutical Services logo
WST
West Pharmaceutical Services
1.9$283.01+0.8%$20.80 billion$1.84 billion74.67Dividend Announcement
Decrease in Short Interest
The Cooper Companies logo
COO
The Cooper Companies
1.7$395.01+2.2%$18.98 billion$2.43 billion82.12Upcoming Earnings
Analyst Report
DENTSPLY SIRONA logo
XRAY
DENTSPLY SIRONA
2.0$60.03+11.6%$11.60 billion$4.03 billion-261.00Earnings Announcement
Dividend Announcement
News Coverage
Gap Down
Quidel logo
QDEL
Quidel
2.4$168.74+2.7%$6.95 billion$534.89 million19.81Gap Down
STAAR Surgical logo
STAA
STAAR Surgical
1.4$105.10+1.0%$4.84 billion$150.18 million553.19Earnings Announcement
Increase in Short Interest
Analyst Revision
Gap Down
Neogen logo
NEOG
Neogen
1.2$84.35+2.9%$4.36 billion$418.17 million73.99
ICU Medical logo
ICUI
ICU Medical
1.5$208.85+0.6%$4.35 billion$1.27 billion55.25Earnings Announcement
Analyst Report
Merit Medical Systems logo
MMSI
Merit Medical Systems
1.7$55.86+0.3%$3.10 billion$994.85 million-105.39Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Atrion logo
ATRI
Atrion
1.1$637.20+1.9%$1.16 billion$155.07 million35.90Dividend Announcement
Gap Down
Cerus logo
CERS
Cerus
1.5$6.60+7.0%$1.03 billion$74.65 million-16.92Earnings Announcement
Gap Down
Meridian Bioscience logo
VIVO
Meridian Bioscience
1.7$22.17+4.9%$909.50 million$253.67 million20.53Analyst Revision
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$10.98+3.5%$760.37 million$154.60 million-47.74Gap Down
Antares Pharma logo
ATRS
Antares Pharma
1.8$4.45+4.5%$708.36 million$123.86 million74.18Upcoming Earnings
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.7$38.71+5.2%$521.69 million$114.51 million-82.36Upcoming Earnings
Utah Medical Products logo
UTMD
Utah Medical Products
1.0$88.14+4.2%$307.22 million$46.90 million27.80Gap Down
This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.